The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
Status:
RECRUITING
Trial end date:
2029-08-30
Target enrollment:
Participant gender:
Summary
This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease